During the corresponding time, Quidelortho Corp recorded a revenue increase by 2.77 % year on year, sequentially revenue grew by 1.79 %. While revenue at the Quidelortho Corp's corporate clients
Quidelortho's Comment on Sales, Marketing and Customers
The company operates in over 140 countries and territories, offering diagnostic products and a broad test portfolio. It sells directly to end users and through distributors for professional use in physician offices, hospitals, clinical and reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care settings, blood banks, and donor centers, as well as for individual, non-professional, over-the-counter use. The business is organized geographically into reportable segments: North America, EMEA, China, JPAC, and Latin America. Revenue is generated through business units including Labs, Transfusion Medicine (Immunohematology and Donor Screening), Point of Care, and Molecular Diagnostics. The company is discontinuing its U.S. donor screening portfolio, specifically the VIP platform and microplate assays, by mid-2026, while continuing to support existing customers and contractual obligations. Diagnostic testing solutions are marketed under brand names such as ADENOPLUS, BIOVUE, FRESHCELLS, INFLAMMADRY, LYRA, METERPRO, MICROVUE, ORTHO, Ortho Clinical Diagnostics, ORTHO OPTIX, ORTHO VERSEIA, ORTHO VISION, QUICKVUE, QUIDEL, QuidelOrtho, QuidelOrtho AUTOMATION ROUTING, QuidelOrtho PERFORMANCE MANAGER, QuidelOrtho RESULTS MANAGER, SAVANNA, SOFIA, SOLANA, THYRETAIN, TRIAGE, VALUMETRIX, VIRENA, and VITROS.
Rosen Law Firm, a renowned global investor rights law firm, has issued a press release announcing the filing of a class action lawsuit on behalf of purchasers of QuidelOrtho Corporation common stock (NASDAQ: QDEL). The lawsuit encompasses the period between February 18, 2022, and April 1, 2024 (the Class Period). Investors who have been impacted by this alleged misconduct are encouraged to secure legal representation before the crucial deadline of June 11, 2024. This article intends to shed light on the implications of the lawsuit and the significance of seeking counsel to protect investors rights.BackgroundQuidelOrtho Corporation, a publicly traded company, has recently faced legal challenges as a result o...
Investigation Underway for Potential Securities Claims against QuidelOrtho CorporationIn the rapidly evolving world of investments, investors rely heavily on accurate and reliable information when making decisions about where to allocate their funds. With this in mind, it is concerning to hear allegations that QuidelOrtho Corporation may have issued misleading business information to the investing public. Rosen Law Firm, a trusted global investor rights law firm, has announced an investigation into potential securities claims on behalf of QuidelOrtho Corporation shareholders. This investigation aims to shed light on the accuracy and transparency of the company s disclosures.Securities laws place a great emp...
Quidelortho’s Comment on Sales, Marketing and Customers
The company operates in over 140 countries and territories, offering diagnostic products and a broad test portfolio. It sells directly to end users and through distributors for professional use in physician offices, hospitals, clinical and reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care settings, blood banks, and donor centers, as well as for individual, non-professional, over-the-counter use. The business is organized geographically into reportable segments: North America, EMEA, China, JPAC, and Latin America. Revenue is generated through business units including Labs, Transfusion Medicine (Immunohematology and Donor Screening), Point of Care, and Molecular Diagnostics. The company is discontinuing its U.S. donor screening portfolio, specifically the VIP platform and microplate assays, by mid-2026, while continuing to support existing customers and contractual obligations. Diagnostic testing solutions are marketed under brand names such as ADENOPLUS, BIOVUE, FRESHCELLS, INFLAMMADRY, LYRA, METERPRO, MICROVUE, ORTHO, Ortho Clinical Diagnostics, ORTHO OPTIX, ORTHO VERSEIA, ORTHO VISION, QUICKVUE, QUIDEL, QuidelOrtho, QuidelOrtho AUTOMATION ROUTING, QuidelOrtho PERFORMANCE MANAGER, QuidelOrtho RESULTS MANAGER, SAVANNA, SOFIA, SOLANA, THYRETAIN, TRIAGE, VALUMETRIX, VIRENA, and VITROS.
Sources:
Quidelortho Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Quidelortho Corp’s corporate clients.
For your research, we’ve provided 9 tables on Quidelortho Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
104.03 %